News Release

Constellation Pharmaceuticals Announces Upcoming Presentations of Lead EZH2 and BET Clinical Programs

February 9, 2018 at 12:00 AM EST

CAMBRIDGE, Massachusetts, February 9, 2018 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research and development in cancer epigenetics, today announced scientific and clinical presentations on its most advanced EZH2 and BET clinical development candidates at three upcoming conferences.

Keystone Symposia for Cancer Epigenetics: New Mechanisms, New Therapies

Title: EZH2 inhibitor treatment results in genome-wide EZH2 re-distribution to genes required for terminal differentiation of germinal center B cells
Session Name: Poster Session 1
Type: Poster Presentation
Presenter: CC Yuan
Date: February 11, 2018
Time: 7:30 to 10:00 p.m. MST (9:30 p.m. to midnight EST)
Location: Breckenridge Ballroom, Beaver Run Resort, Breckenridge, Colorado, USA

Epigenetics Conference: From Mechanisms to Disease

Title: Utilizing chemical biology to identify novel strategies targeting histone acetyl signaling in cancer
Session Name: Heterochromatin and Chemical Biology Approaches
Type: Oral Presentation
Presenter: Rob Sims
Date: February 17, 2018
Time: 11:15 to 11:45 a.m. EST
Location: Fiesta Americana Condesa Hotel, Cancun, Mexico

2018 International Targeted Anticancer Therapies (TAT) Congress/ESMO

Title: A Phase I Study of CPI-0610, a Bromodomain and Extra Terminal Protein (BET) Inhibitor in Patients with Relapsed or Refractory Lymphoma
Presentation Number: 41O
Session Name: Proffered Paper Session 2
Type: Oral Presentation
First Author: Kristie A. Blum
Presenter: Adrian Senderowicz
Date: March 6, 2018
Time: 11:00 to 11:12 a.m. CET (5:00 to 5:12 a.m. EST)
Location: Room Scene AB, Paris Marriott Rive Gauche, Paris, France

Title: A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Preliminary Safety in Patients with B-Cell Lymphomas
Presentation Number: 42O
Session Name: Proffered Paper Session 2
Type: Oral Presentation
First Author: Wael Harb
Presenter: Claudia Lebedinsky
Date: March 6, 2018
Time: 11:15 to 11:27 a.m. CET (5:15 to 5:27 a.m. EST)
Location: Room Scene AB, Paris Marriott Rive Gauche, Paris, France

About CPI-1205
CPI-1205 is an experimental small molecule therapy that is designed to inhibit the enzymatic activity of Enhancer of Zeste Homolog 2 (EZH2). The function of EZH2 is to selectively suppress gene expression of several tumor suppressor pathways and pathways that contribute to drug resistance.

About CPI-0610
CPI-0610 is an experimental small-molecule therapy designed to inhibit the expression of several genes involved in cancer and fibrosis, including MYC, BCL2, NF-κB and TGF-β-induced collagen by binding to a family of proteins known as bromodomain and extra-terminal (BET).

About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small-molecule therapies based on its pioneering research in cancer epigenetics. With a decade of experience in the field, the company has an unparalleled understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment. Constellation is translating these insights to advance the company’s two lead clinical programs, CPI-1205 and CPI-0610, and in novel targets for which cancer epigenetics may help overcome resistance mechanisms to currently available treatment options.

For more information, please visit

Media contact:
Katie Engleman
+1 (910) 509-3977